140 reports of this reaction
1.4% of all ATOGEPANT reports
#13 most reported adverse reaction
THERAPEUTIC PRODUCT EFFECT INCOMPLETE is the #13 most commonly reported adverse reaction for ATOGEPANT, manufactured by AbbVie Inc.. There are 140 FDA adverse event reports linking ATOGEPANT to THERAPEUTIC PRODUCT EFFECT INCOMPLETE. This represents approximately 1.4% of all 9,899 adverse event reports for this drug.
Patients taking ATOGEPANT who experience therapeutic product effect incomplete should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
THERAPEUTIC PRODUCT EFFECT INCOMPLETE is a less commonly reported adverse event for ATOGEPANT, but still significant enough to appear in the safety profile.
In addition to therapeutic product effect incomplete, the following adverse reactions have been reported for ATOGEPANT:
The following drugs have also been linked to therapeutic product effect incomplete in FDA adverse event reports:
THERAPEUTIC PRODUCT EFFECT INCOMPLETE has been reported as an adverse event in 140 FDA reports for ATOGEPANT. This does not prove causation, but indicates an association observed in post-market surveillance data.
THERAPEUTIC PRODUCT EFFECT INCOMPLETE accounts for approximately 1.4% of all adverse event reports for ATOGEPANT, making it a notable side effect.
If you experience therapeutic product effect incomplete while taking ATOGEPANT, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.